Abstract: Pre-clinical and clinical data indicate differences in the responses of melanoma and carcinoma tumours to electrochemotherapy. The purpose of this study was to investigate the origin of this difference, whether it is due to the intrinsic difference in tumour cell susceptibility to the chemotherapeutic, or due to the tumour micro-environment. For this purpose, we performed a pre-clinical study in B16F1 melanoma and TS/A carcinoma tumours in mice, in which the antitumour effectiveness of electrochemotherapy with bleomycin, the intrinsic sensitivity of tumour cells in vitro, the pharmacokinetics of bleomycin in plasma and tumours, and the vascularization of tumours in vivo were evaluated. The results of the treatment show that carcinoma was significantly more responsive to electrochemotherapy than melanoma. This effect cannot be ascribed to the intrinsic sensitivity of these cells, as melanoma cells were more sensitive than carcinoma cells in vitro. The difference in responses could be ascribed to differences in the pharmacokinetics of bleomycin; at the time of electroporation in carcinomas, more bleomycin was accumulated. This effect could be due to differences in tumour vascularization, as carcinoma tumours had numerous well-distributed, small blood vessels, while melanomas were less vascularized, exhibiting predominantly larger vessels. In conclusion, this study provides evidence on the importance of the tumour micro-environment, particularly the tumour vasculature, in the responses of the tumours to bleomycin electrochemotherapy. Vasculature is important for the pharmacokinetics of bleomycin, influencing drug accumulation and drug distribution in tumours, and might be used as a predictive factor for the tumour response to electrochemotherapy.
Electrochemotherapy is a clinically applied local ablative technique with effectiveness comparable to other local ablative techniques [1] [2] [3] [4] [5] [6] . This technique is based on electroporation, a physical delivery method, where the application of electric pulses to the tumour tissue enhances the cell membrane permeability and therefore significantly increases the cellular uptake of chemotherapeutic drugs, such as cisplatin or bleomycin [7, 8] .
The most commonly used drug in electrochemotherapy is bleomycin. This drug is administered intravenously, subcutaneously or intramuscularly, as it is not absorbed from the gut. Due to its hydrophilic nature, bleomycin is generally not bound to plasma proteins, and its entry into the cells is limited and primarily mediated by endocytosis [9] . The primary target for the cytotoxic action of bleomycin in the cell is DNA. In the presence of cofactors, that is oxygen, Fe(II) and a reducing agent, bleomycin becomes activated and causes oxidative damage to the deoxyribose of nucleotides, which further leads to singleand double-stranded DNA breaks and cell apoptosis [10] . Bleomycin is inactivated by a bleomycin hydrolase in various tissues, primarily in plasma and liver, whereas the activity of the enzyme is low in the skin and lungs, causing tissue-specific toxicity [11, 12] . As two-thirds of administered bleomycin is eliminated from the kidneys, renal insufficiency can delay bleomycin elimination. The effective cytotoxic dose of bleomycin is significantly lower in electrochemotherapy compared to the dose used in standard chemotherapeutic regimens [3, 13, 14] . The first pharmacokinetic study of bolus bleomycin administration, which is used in electrochemotherapy, has recently been conducted in elderly patients, shortly after a new analytical method for the determination of bleomycin in tissue, serum and plasma samples was developed [15] . The observed pharmacokinetics of the drug in recent studies suggested lowering the bleomycin dose in elderly patients [16, 17] .
In addition to lowering the drug dose for effective electrochemotherapy, other open questions remain. According to the pre-clinical and clinical data, as well as meta-analysis [18] [19] [20] , non-melanoma tumours respond better to electrochemotherapy than melanomas. This difference in tumour response according to the tumour type has not been thoroughly elucidated to date.
The aim of this study was to explore the underlying mechanisms that govern the differences in the responses in melanoma and carcinoma tumours. The effectiveness of electrochemotherapy was compared with that of intravenous bleomycin administration in melanoma and carcinoma mouse models with regard to the timing between bleomycin injection and tumour electroporation. The observed difference in the response was compared with the intrinsic sensitivity of tumour cells in vitro, the pharmacokinetics of bleomycin in plasma and tumours, and the vascularization of tumours in vivo.
Materials and Methods
Cell lines. Two different murine cell lines, B16F1 melanoma cells (American Type Culture Collection (ATCC) Manassas, VA, USA, bought in 2011) and TS/A carcinoma cells (generously provided by Prof. Giraldi T.; University of Trieste, Italy, and were tested for authentication in 2017 at IDDEx Bioresearch laboratory) [21] , were used in the in vitro and in vivo experiments. Both cell lines were maintained in advanced essential medium (AMEM, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% of foetal bovine serum (Gibco) in a humidified atmosphere at 37°C and 5% CO 2 . Two days after plating the cells, when confluency was approximately 80%-90%, the cells were used for the in vitro experiments or induction of tumours in vivo. In all experiments, cells no more than 5th passage were used.
Intrinsic effectiveness of electrochemotherapy with bleomycin in vitro. The cells were trypsinized, centrifuged and resuspended in electroporation buffer (125 mM sucrose, 10 mM K 2 HPO 4 , 2.5 mM KH 2 PO 4 , 2 mM MgCl 2 9 6H 2 O) [22] , and 80 ll of a 1 9 10 6 cell suspension was mixed with 20 ll bleomycin (Bleomycin medac, Medac, Wedel, Germany) dissolved in phosphate-buffered saline (PBS, Gibco) to obtain different final concentrations (0-2 lg/ml) and half of that mixture (50 ll) was incubated for 5 min. at room temperature (22°C). For electrochemotherapy, the other half of the mixture of cells with bleomycin (50 ll) was placed between two parallel stainless steel plate electrodes with a 2-mm gap in-between and exposed to eight square wave electric pulses with amplitude over distance ratio 1300 V/cm, duration 100 ls and frequency 1 Hz generated by the electric pulse generator GT-01 (Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, Slovenia). After electroporation, the cells were incubated for 5 min. at room temperature. Immediately after incubation, the cells (with and without electric pulse application) were diluted in 2 ml fresh AMEM (Gibco) supplemented with 10% foetal bovine serum (Gibco). Subsequently, suspensions of 1000 (without electric pulse application) or 2000 (with electric pulse application) cells in 100 ll of media per well were plated onto 96-well plates (Corning Incorporated, NY, USA) and incubated for 72 hr at 37°C in a humidified incubator with 5% CO 2 . To determine cell viability, the Presto Blue â assay (Thermo Fisher Scientific) was used according to the manufacturer's instructions. To measure the fluorescence intensity of resorufin, a microplate reader (Infinite 200, Tecan, M€ annedorf, Switzerland) was used. The cytotoxicity of treatments was determined at IC 50 (inhibitory concentration; the concentration of drug which decrease cell survival for 50%) and IC 10 (the concentration of drug which decreases cell survival for 10%) values.
Animals and tumour induction. For tumour induction, 1 9 10 6 B16F1 melanoma or TS/A carcinoma cells in 100 ll of phosphate-buffered saline (PBS) were injected subcutaneously in the right flank of 7-to 8-week-old female, C57Bl/6 (melanoma) or BALB/c (carcinoma) mice (Envigo, Udine, Italy), weighing 20-22 g. The animals were kept at a constant room temperature with a 12-hr light cycle. Food and water were provided ad libitum. All animal experiments were conducted in accordance with the principles and procedures outlined in the guidelines for animal experiments of the EU directives (2010/63/EU and 86/609/ EEC), 'European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes ', 1986 , and the 'Guiding Principles in the Use of Animals in Toxicology', adopted by the Society of Toxicology in 1989, the guidelines for the welfare of animals in experimental neoplasia [23] , calculated by the formula for the ellipsoid a 9 b 9 c 9 p/6, where a, b and c are perpendicular diameters, were randomly divided into experimental groups containing six animals each and weighed. In the treatment groups, each tumour was electroporated at different time-points (5, 15, 30, 60 and 120 min.) after intravenous bleomycin (5 mg/kg; 1492.5 mg/ml, 100 lg, 70 ll per mouse weighing 21 g) injection. Tumours were measured every second day after the treatment, and based on the calculated tumour volume, the tumour doubling time was determined as the time in which the tumour reached double the initial volume. In addition, the tumour growth delay was estimated as the difference between the tumour doubling time of the treatment and control groups. The animals with no trace of tumours over the 100 days after treatment were considered cured (tumour cure). The animal body-weight and well-being (changes in behaviour, coat and skin condition) were monitored daily during the experiment as the indicator of systemic toxicity of the therapy.
Blood and tumour samples collection after injection of bleomycin only. The experiments were performed when tumours reached approximate tumour volume of 45 mm 3 . The mice were randomly divided into the experimental groups, containing 12 animals in two separate experiments (six animals in each), one experimental group for each time-point (1, 5, 10, 20, 60 and 120 min.). Each mouse received 5 mg/kg (1492.5 mg/ml, 100 lg and 70 ll per mouse weighing 21 g) of bleomycin intravenously. At 1, 5, 10, 20, 60 and 120 min. after bleomycin injection, blood and tumour samples were collected. Blood was collected from the intraorbital sinus into a blood collection tube (Vacuette serum tube with gel; Greiner Bio-One International AG, Kremsm€ unster, AU) and centrifuged for 10 min. at 3000 rpm. Only the upper phase (plasma) was pipetted into a new microcentrifuge tube and stored at À80°C until further analysis. The tumours were excised, weighed and immediately stored at À80°C until further analysis.
Blood and tumour samples collection after electrochemotherapy. As described above, when the tumour volume reached 45 mm 3 , the mice were divided into groups containing 12 animals in two separate experiments (six mice in each) and each mouse received 5 mg/kg (1492.5 mg/ml, 100 lg, 70 ll per mouse weighing 21 g) of bleomycin. Electrochemotherapy was performed 1 min. after bleomycin injection. The tumours (6-7 mm in the largest diameter) were placed between plate electrodes 8-mm gap, so that the whole tumours were encompassed and exposed to eight pulses with voltage 960 V, pulse duration 100 ls and frequency 1 Hz (pulse generator: Cliniporator, IGEA S.r.l., Carpi, Italy). To ensure better contact between the electrodes and tumour, a water-based conductive gel (Gel G006 ECO, FIAB, Vicchio, Italy) was used. The electric field distribution should be adequate as calculated by numerical modelling [24] . Blood and tumour samples were collected at 5, 20 and 120 min. after therapy. The samples were collected and stored as described above.
Sample preparation and chemical analysis. Frozen tumours were ground in the presence of liquid nitrogen and quantitatively transferred into a centrifuge tube. The suspension was sonicated in an ultrasonic bath (VWR 550D, Radnor, PA) for one hour at 35 kHz and centrifuged at 8600 9 g for 20 min. Next, the supernatant was filtered through 0.45 lm Minisart â NML (Sartorius, G€ ottingen, Germany) cellulose acetate syringe filters. The 50 ll plasma samples were diluted to 3 ml with 0.1% formic acid and filtered through 0.45 lm Minisart â NML cellulose acetate syringe filters. Tumour and plasma filtrates were loaded onto pre-conditioned Oasis HLB 30 mg/(1 cc) cartridges (Waters Corp., Milford, MA, USA), and subsequently, the sorbent was dried under vacuum for 30 min. and eluted using 0.5 ml of MilliQ water/methanol (6/ 4) and twice with 0.5 ml acetonitrile. The sample extracts were blown down to 1 ml using nitrogen before the addition of 25 ll epirubicin at a concentration of 2 lg/ml. The samples were kept frozen until liquid chromatography coupled to high-resolution mass spectrometry analysis, which was performed within 1 month.
Quantitative analysis was performed with Shimadzu Nexera 92 ultra high-performance liquid chromatography (Kyoto, Japan) coupled to a linear ion trap quadrupole 4500 QTRAP mass spectrometer (Sciex, Framingham, MA, USA). The liquid chromatography was equipped with a solvent delivery system and an auto sampler. The injection volume was 5.0 ll. Separation was achieved at room temperature using a 5-cm-long Acquity UPLC â BEH Amide (Waters Corp.) column with 1.7 lm particle size and 2.1 mm internal diameter. Bleomycin was analysed under electrospray ionization in positive mode. The mobile phases were (A) 10 mM ammonium formate with 0.1% formic acid and (B) acetonitrile. The gradient started with 95% A, which was decreased to 50% in 2 min., decreased to 40% in the following 2 min., increased back to 95% in 0.5 min. and maintained until 6 min. The flow rate was 0.3 ml/min. 4500 QTRAP was operated in positive electrospray ionization mode with the following settings: curtain gas: 20 psi; collision gas: medium; source temperature: 70°C; ion spray voltage: 5500 V; ion source gas 1: 30 psi; ion source gas 2: 20 psi. The mass spectrometer was operated in enhanced product ion mode at the following compound parameters for the quantitative transition of bleomycin (m/z 738.2 > m/z 707.5-708.7): entrance potential: 10 V; declustering potential: 60 V; and collision energy: 23 V. The data station operating software was Analyst v1.6.3. As a part of quality control, we determined the accuracy and precision of the analytical method prior to each sequence of measurements. The accuracy was determined as the difference between the spiked and experimentally determined values, and ranged from 0 to 14% and from 1 to 17% for plasma and tumour matrices, respectively. The precision was expressed as the instrumental repeatability, which was determined for three consecutive injections of the same sample, and as the method repeatability for three individual plasma or tumour blanks spiked with the same amount of bleomycin. The injection repeatability was 3.4% and 5.3% for plasma and tumour matrices, respectively. The method repeatability ranged from 3.7 to 4.9% in case of plasma and from 3.3 to 10.6% for tumours. The standard and quality control samples were prepared from plasma or tumours obtained from animals that had never before been exposed to bleomycin pharmacotherapy.
Pharmacokinetic data analysis. Pooled bleomycin concentration data derived from 12 independent measurements either in plasma, in untreated or in electrochemotherapy-treated tumour tissues, were analysed. We determined the following pharmacokinetic parameters:
C 0 (concentration of bleomycin in plasma at time 0) value was extrapolated from the natural logarithm (ln) concentration versus time plot for each pooled data set. Furthermore, the area under the plasma concentration-time curve (AUC) using the trapezoid method from time 0 to infinity (∞)(AUC 0?∞ ) and plasma clearance (CL) were calculated.
Elimination rate constant (k el) was determined from the plot ln concentration versus time curve and half-time was calculated as
Histology. Three mice bearing control untreated B16F1 melanoma or TS/A carcinomas were humanely killed by cervical dislocation when the tumours reached volume of approximately 45 mm 3 . The tumours were excised and fixed overnight in IHC zinc fixative (BD Pharmingen, BD Biosciences, San Jose, CA, USA), embedded in paraffin and then cut to 2-lm-thick consecutive sections. The first section was immunohistochemically stained with rabbit polyclonal antibodies against CD31 (ab28364, Abcam, Cambridge, MA, USA) at dilution 1:1000. A peroxidase-conjugated streptavidin-biotin system (Rabbit specific HRP/DAB detection IHC kit, ab64261, Abcam) was used as the colourogenic reagent followed by haematoxylin counterstaining. To determine collagen, the second consecutive tumour section was stained using Masson`s trichrome. The images of immunohistochemically stained sections were captured with a DP72 CCD camera (Olympus, Hamburg, Germany) connected to a BX-51 microscope (Olympus). At each slide, five fields of view in viable tumour tissue were chosen randomly and imaged under the light microscopy. The number and area of CD31-positive blood vessels were determined on acquired images using AxioVision imaging software with custom-made module that contoured the vessels on the images, and the marked vessels were manually verified and corrected, if needed. Then, the number of vessels and their area were averaged for each tumour type. In addition, the average area per vessel was calculated by dividing the average area of vessels per tumour section with the number of vessels per tumour section. The collagen was determined on the acquired images using CellSens Dimensions software (Olympus) by measuring the area. These immunohistochemical analyses were performed by two independent investigators who were blinded to the tumour type.
Statistical analysis. For statistical analysis, a SigmaPlot Software (Systat Software, Chicago, IL, USA) and GraphPad Prism 7.03 (GraphPad Software, Inc., La Jolla, CA, USA) were used. Firstly, data were tested for normality of distribution with the Shapiro-Wilk test. The differences between the experimental groups were statistically evaluated by t-test or one-way analysis of variance (one-way ANOVA) followed by a Holm-Sidak test for multiple comparison. The correlation (R) between tumour growth delay and bleomycin amount in the tumours or plasma was evaluated with linear Pearson correlation analysis. A p value of less than 0.05 was considered to be statistically significant.
Results
Antitumour effectiveness of electrochemotherapy.
In vitro cell survival. Intrinsic sensitivity to bleomycin and electrochemotherapy was measured in vitro in both cell lines. TS/A carcinoma cells were resistant to short bleomycin exposure, whereas B16F1 melanoma cells were sensitive to bleomycin exposure. In both cell lines, electroporation potentiated bleomycin cytotoxicity, in B16F1 melanoma cells up to 164 times at IC 50 value (up to 24 times at IC 10 value) and in TS/A carcinoma cells 1000 times at IC 10 value ( fig. 1) . These data indicate a significantly higher sensitivity (p < 0.001) of B16F1 melanoma cells with and without electroporation to bleomycin compared to TS/A carcinoma cells.
In vivo antitumour effectiveness. Difference in the antitumour effectiveness of electrochemotherapy with intravenously administered bleomycin was compared in two murine tumour models, B16F1 melanoma and TS/A carcinoma, with the same drug dosage and at equal tumour volumes but with the different time intervals of the drug distribution in the tumours.
In the B16F1 melanoma tumour model, electrochemotherapy resulted in significant tumour growth delay without tumour cure ( fig. 2A, table 1 ). Maximal tumour growth delay of approximately 20 days was observed when electric pulses were applied at 5 and 15 min. after the intravenous injection of bleomycin. Thereafter, by increasing the time delay between the injection of bleomycin and electroporation of the tumour, a significantly shorter tumour growth delay was observed (table 1) . Electrochemotherapy did not cause any systemic toxicity.
In TS/A carcinoma tumour model, the efficiency of electrochemotherapy was the most potentiated when electric pulses were applied at 5 min. after bleomycin injection, resulting in 67% complete responses and significant tumour growth delayup to 40 days ( fig. 2B, table 2) . Furthermore, electroporation of the tumours at 15 min. after bleomycin injection resulted in 50% complete responses and a significant tumour growth delay of up to 28 days ( fig. 2B ). As observed in B16F1 melanoma and TS/A carcinoma, by increasing the time delay between injections of bleomycin, the electroporation of tumours resulted in a significant shorter tumour growth delay ( fig. 2, table 2 ). Electrochemotherapy did not cause any systemic toxicity.
According to the measured response of the electrochemotherapy-treated tumours, we speculated that a higher bleomycin concentration in a shorter time was accumulated in TS/A tumours than in B16F1 melanomas. To explore the drug accumulation, we determined the drug pharmacokinetics in the plasma and tumours.
Pharmacokinetics of bleomycin in plasma and tumour tissue.
Pharmacokinetics in plasma. Firstly, we explored the potential difference in the pharmacokinetics of bleomycin in plasma from the two strains of mice that were syngeneic to the two tumour models. One minute after bleomycin injection, 10.9 AE 1.0 mg/l of bleomycin was detected in the plasma of the C57Bl/6 mice, and 19.9 AE 0.7 mg/l was detected in BALB/c mice ( fig. 3 ). The bleomycin concentration declined immediately after the injection of bleomycin by a fast and slow component (table 3) . The calculated pharmacokinetic parameters demonstrated that the systemic exposure of mice to bleomycin expressed by AUC is similar in both mouse strains. Similarly, plasma clearance and bleomycin elimination halftime from plasma did not differ between the two strains.
Electroporation of tumours, due to the vasoconstriction effect on underlying kidney and its blood vessels, similarly increased the plasma AUC of bleomycin in both C57Bl/6 (2.6 times) and BALB/c (2.2 times) mouse strains (table 3) . In addition, the plasma clearance rate after electroporation of tumours was decreased, and the elimination pattern changed from two-phase to one-phase elimination. The elimination half-time time of bleomycin from plasma in both mice strains Fig. 1 . B16F1 melanoma and TS/A carcinoma cell survival after short exposure (5 min.) to bleomycin (BLM) alone or in combination with electric pulse application (electrochemotherapy, ECT). The data, eight repetitions from two independent experiments, represent the means AE SEM. *TS/A ECT group (white circles) versus B16F1 ECT (white triangles); p < 0.001. Fig. 2 . Antitumour effectiveness of electrochemotherapy in B16F1 melanoma grown in C57Bl/6 mice (A) and TS/A carcinoma grown in BALB/c mice (B) depending on the interval between the intravenous bolus bleomycin (BLM, 5 mg/kg) administration and electroporation of the tumour (EP). The data represent the means AE SEM (n = 6).
after electroporation was similar to slow phase elimination half-time without electroporation ( fig. 3, table 3 ).
Pharmacokinetics in the tumours. Secondly, we explored the potential difference in pharmacokinetics in the two tumour models. After intravenous injection of bleomycin, its concentration in both tumour types increased in time up to 5 min. post-injection ( fig. 4) . Thereafter, the bleomycin concentration started to decline. The amount of bleomycin taken up and expressed by AUC was significantly higher (4.9 times) in TS/A carcinoma tumours (36,147 mg 9 min./l) than that in B16F1 melanoma tumours (7348 mg 9 min./l). When the tumours were electroporated, the amount of bleomycin in both tumour models was further increased, that is 26 times in B16F1 melanoma tumours (188,575 mg 9 min./l) and two times in TS/A carcinoma tumours (70,356 mg 9 min./l) at the AUC. Electroporation prolonged the elimination of bleomycin from the tumours; after 120 min. in both tumour models, bleomycin was still present, while after the injection of bleomycin alone in B16 F1 tumours, bleomycin was undetectable at 60 min. post-injection and in TS/A tumour at 120 min. (fig. 4) .
Correlation between bleomycin concentration and tumour response. The pooled data on the responses of both tumour models indicate that the responses of the tumours were highly correlated (R 2 = 0.979) with the bleomycin concentration in the tumours at the time of electroporation ( fig. 5A) . Specifically, the melanoma tumours that were less responsive had lower bleomycin concentrations than the carcinoma tumours where a higher bleomycin concentration was detected. However, the plasma bleomycin concentration did not correlate with the bleomycin concentration in tumours when both tumour models and mouse strains were analysed ( fig. 5B) . Notably, the plasma bleomycin concentration was only correlated within each mouse strain; therefore, by measuring the plasma bleomycin concentration, we cannot predict the bleomycin concentration in the tumours and thus tumour responses. These results indicate that the difference in bleomycin accumulation and distribution in different tumour models should be related to the features of the tumour micro-environment, that is tumour vascularization and perfusion.
Tumour histology. To explore the possible influence of the tumour micro-environment on pharmacokinetics of the bleomycin in the tumours, the vascularization and collagen content in the TS/A carcinoma and B16F1 melanoma were compared. The tumour collagen content, as an indicator of the extracellular space, was similar in the two tumour models ( fig. 6A, table 4 ). The number of the tumour vessels and their sizes (area) were determined in the immunohistochemically stained tumour sections. The TS/A carcinoma presented with nearly three times higher number of blood vessels than B16F1 melanoma. However, the average area of the vessels was lower, measuring approximately 845 lm 2 , while in melanoma, the average area was almost two times larger, measuring approximately 1363 lm 2 . When calculated the ratio of average area per vessel, the vessels in B16F1 melanoma were four times larger than in TS/A carcinoma ( fig. 6B, table 4 ).
Discussion
The results of the present study might explain certain aspects of the differences in the responses to electrochemotherapy in different histological types of malignant tumours. We provided evidence that intrinsic susceptibility of tumour cells to cytostatic bleomycin with or without electroporation is important, but the influence of the tumour micro-environment (stroma), specifically the vascularization of the tumours, can override the intrinsic susceptibility of the tumour cells by significantly influencing the pharmacokinetic of bleomycin in the tumours. Consequently, the high accumulation and good distribution of bleomycin in the tumours contribute to the overall effectiveness of electrochemotherapy. Differences in response rate of the tumours of different histological types to electrochemotherapy were previously demonstrated in the early pre-clinical studies [25] [26] [27] [28] [29] , as well as the most recent clinical studies [2, 3] . Compared to melanoma, the objective response rates to electrochemotherapy were higher in the group of carcinomas and sarcomas [18] . In previous studies, the intrinsic susceptibility of the cells to bleomycin was an important predictive factor for the antitumour effectiveness. Several studies have demonstrated the differences in cell sensitivity to electrochemotherapy [25, [30] [31] [32] [33] . However, the results of the present study demonstrated that other factors, related to the tumour micro-environment, also influence the tumour response to electrochemotherapy. The data obtained from in vivo mice models indicated a better response to electrochemotherapy in TS/A carcinoma than in B6F1 melanoma, in contrast to the in vitro results. In order to make the results of both tumour models comparable, we performed the therapy at the same initial tumour volume, 45 mm 3 . Although melanoma tumours had a higher growth rate, this should not affect the response to the therapy, as it was shown in previous studies that higher growth rate of tumours does not correlate to the response to electrochemotherapy [34, 35] . However, the drawback of the study is that tumours were grown in two different strains of mice due to the syngeneity of used tumour cell lines. In both groups of tumours, the best responses were recorded when tumours were electroporated up to 15 min. after bleomycin injection, indicating the fast accumulation of bleomycin in both tumour models. This result is consistent with that of a previous study, where in melanoma B16 tumours, the optimal 3-min. interval between the intravenous drug injection and electroporation of the tumour was demonstrated [19] . However, at identical time-points after injection of bleomycin, significantly higher bleomycin concentrations were achieved in TS/A tumours than in B16F1 tumours, which correlated with the observed tumour responses to electrochemotherapy; longer tumour growth delay and tumour cures were obtained in TS/A carcinoma. The bleomycin concentration in plasma did not follow the same pattern, and the bleomycin concentration in plasma was not correlated with tumour response and cannot thus be used to predict tumour responses to electrochemotherapy, indicating that the mechanisms responsible for different bleomycin accumulation and distribution in the tumour influence the responses of particular histological tumour types to electrochemotherapy.
In the present study, the electroporation of tumours increased AUC in plasma in both mouse strains. This unexpected result could be explained by the size of the animals and subcutaneous location of the tumours on the flank. The subcutaneous tumours were located on the flank above the kidney; therefore, application of electric pulses could affect kidney perfusion with the delivery of electric pulses, especially when the electrodes are firmly positioned around the tumour. Due to the known vascular effects of electric pulses, kidney perfusion could be transiently reduced, thus having effect on pharmacokinetics of bleomycin. Such effect can be observed only in small animals like mice, where internal organs are in the close vicinity of the electrodes [36] [37] [38] . Therefore, we can presume that electroporation of tumours also caused vascular effects on adjacent normal tissues; thus, the constriction of blood vessels in kidney might have changed the AUC and the plasma clearance of the bleomycin.
Tumour micro-environment is composed of extracellular matrix, stromal cells, immune cells and tumour vessels [39] , which can all contribute to the antitumour response of electrochemotherapy. In the present study, we focused on tumour vasculature, which has not yet been explored. The vasculature is important for the drug distribution, while electroporation can affect it and change the pharmacokinetics of the drug by the so-called vascular lock causing drug accumulation. The vascular lock effect was observed immediately after electroporation as a result of the vasoconstriction of afferent arterioles, causing bleomycin entrapment in the tumours and consequently prolonged exposure of tumour and endothelial cells to bleomycin. Besides the vascular lock effect, which lasts for several hours, in electrochemotherapy due to bleomycin, the vascular disrupting effect follows the vascular lock and induces a profound long-lasting decrease in the local blood flow. This effect is more evident in smaller tumour vessels than in bigger tumour vessels [31, 38, 40, 41] .
In the present study, we compared the TS/A carcinoma, with more functional vasculature presented by numerous but small vessels, compared to B16F1 melanoma with less functional vasculature presented by fewer and larger tumour blood vessels. Additionally, the distribution of the blood vessels was more even in carcinoma than in melanoma. Based on this observation, we can explain the higher initial bleomycin concentration in carcinoma than in melanoma tumours, which is due to more functional vessels and their denser organization. Electroporation of tumours increased the concentration of bleomycin in melanoma tumours more than in carcinomas; however, this effect did not result in better antitumour effectiveness of electrochemotherapy in melanoma. Electroporation induced the vasoconstriction of the vessels entrapped bleomycin in the large vessels and formed lacunas in melanoma tumours, preventing bleomycin from entering the tumour extracellular matrix and thus cells. Additionally, as large vessels are less sensitive to electrochemotherapy than small vessels [42] , the antivascular effect of electrochemotherapy was not so manifested in melanomas. Altogether, the vascularization, which is different in different tumours, is important for drug accumulation and distribution.
Therefore, in a clinical setting of electrochemotherapy, the vascularization could be a potential predictive factor for the effectiveness of electrochemotherapy. Tumours with functional and well-organized vascularization should respond better to electrochemotherapy than tumours with poor or non-functional vasculature. This effect was demonstrated in the clinical setting. Tumours in pre-irradiated areas respond worse to electrochemotherapy than tumours in non-irradiated areas [18, 43, 44] . In the pre-irradiated tumours, a tumour-bed effect with reduced vasculature is the predominant factor influencing the radiation response of tumours [45] [46] [47] [48] .
In conclusion, the present study provides the first evidence of the importance of tumour vasculature for the response of the tumours to electrochemotherapy with bleomycin. Based on the comparison of the carcinoma and melanoma models used in the present study, we concluded that the distribution and size of vessels influence bleomycin accumulation and distribution in the tumours. Therefore, the treatment response to electrochemotherapy is not only influenced by the intrinsic susceptibility of tumour cells of different histological types, but the tumour micro-environment (vascularization) plays an even more important role in determining the tumour response to electrochemotherapy and might be used as a predictive factor.
